Paradigm Biopharmaceuticals Ltd.ASX: PAR

First mps-vi patient dosed under phase 2 trial in Brazil

Sep 30, 2021 at 4:54 AM UTC · Issued by Paradigm Biopharmaceuticals Ltd.

Paradigm Biopharmaceuticals Ltd has released a press release.

View Attachment